Cimetidine
- Generic Name
- Cimetidine
- Brand Names
- Good Sense Heartburn Relief, Tagamet
- Drug Type
- Small Molecule
- Chemical Formula
- C10H16N6S
- CAS Number
- 51481-61-9
- Unique Ingredient Identifier
- 80061L1WGD
- Background
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
- Indication
Cimetidine is indicated to reduce gastric acid secretion and to treat the following disease states: duodenal ulcers, non-malignant gastric ulcers, gastroesophageal reflux disease, and pathological hypersecretion associated with Zollinger-Ellison Syndrome, systemic mastocytosis, and multiple endocrine adenomas. It is indicated for prophylaxis of recurrent gas...
- Associated Conditions
- Cystic Fibrosis (CF), Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Gastrointestinal Symptoms, Heartburn, Active Duodenal ulcer, Benign gastric ulcers, Develop NSAID-induced gastric ulcers, Recurrent Ulcers, Duodenal and Gastric
- Associated Therapies
- -
Effect of Oral Cimetidine in the Protoporphyrias
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Amy K. Dickey, M.D.
- Target Recruit Count
- 20
- Registration Number
- NCT05020184
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 129
- Registration Number
- NCT04862585
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug-drug Interaction Study of Gepotidacin
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 64
- Registration Number
- NCT04493931
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Fakultas Kedokteran Universitas Indonesia
- Target Recruit Count
- 26
- Registration Number
- NCT04018131
- Locations
- 🇮🇩
Faculty of Medicine Universitas Indonesia, Jakarta Pusat, Jakarta, Indonesia
Effect of Cimetidine on the PK of Imeglimin
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Poxel SA
- Target Recruit Count
- 16
- Registration Number
- NCT03618316
- Locations
- 🇬🇧
Hammersmith Medicines Research (HMR), London, United Kingdom
Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2022-06-02
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03380455
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men
- Conditions
- Interventions
- First Posted Date
- 2017-10-11
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 45
- Registration Number
- NCT03307252
- Locations
- 🇩🇪
CTC North GmbH & Co. KG, Hamburg, Hamburg, Germany
Proton Pump Inhibitors and Risk of Community-acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2015-09-22
- Target Recruit Count
- 4238504
- Registration Number
- NCT02555852
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02202512
- Locations
- 🇩🇪
1333.43.1 Boehringer Ingelheim Investigational Site, Berlin, Germany
Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 343
- Registration Number
- NCT02157376
- Locations
- 🇨🇳
Research Site, Zhanjiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.